JO2334B1 - Drospirenone for hormone replacement therapy - Google Patents
Drospirenone for hormone replacement therapyInfo
- Publication number
- JO2334B1 JO2334B1 JO200110A JOP20010010A JO2334B1 JO 2334 B1 JO2334 B1 JO 2334B1 JO 200110 A JO200110 A JO 200110A JO P20010010 A JOP20010010 A JO P20010010A JO 2334 B1 JO2334 B1 JO 2334B1
- Authority
- JO
- Jordan
- Prior art keywords
- estrogen
- beta
- menopausal
- drospirenone
- hormone replacement
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6 beta , 7 beta ; 15 beta ; 16 beta -dimethylene-3-oxo-17 alpha -preg-4-ene-21, 17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00200183 | 2000-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO2334B1 true JO2334B1 (en) | 2006-06-28 |
Family
ID=38170612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JO200110A JO2334B1 (en) | 2000-01-18 | 2001-01-11 | Drospirenone for hormone replacement therapy |
Country Status (7)
Country | Link |
---|---|
AR (1) | AR035633A1 (en) |
CO (1) | CO5280075A1 (en) |
HR (1) | HRP20070360B1 (en) |
JO (1) | JO2334B1 (en) |
PE (1) | PE20011051A1 (en) |
SA (1) | SA01210754B1 (en) |
UA (2) | UA89180C2 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4426601A1 (en) * | 1994-07-27 | 1996-02-01 | Schering Ag | Use of a combination product containing a competitive progesterone antagonist and a progestogen for the manufacture of a medicament for the treatment of endometriosis or Leiomyomata uteri |
DE19654609A1 (en) * | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutic progestogens for the treatment of premenstrual dysphoric disorder |
DK1380301T3 (en) * | 1999-08-31 | 2009-04-20 | Bayer Schering Pharma Ag | Pharmaceutical composition of ethinylestradiol and drospirenone for use as a contraceptive |
-
2001
- 2001-01-11 JO JO200110A patent/JO2334B1/en active
- 2001-01-15 PE PE2001000035A patent/PE20011051A1/en active IP Right Grant
- 2001-01-17 CO CO01003045A patent/CO5280075A1/en not_active Application Discontinuation
- 2001-01-17 AR ARP010100199 patent/AR035633A1/en not_active Application Discontinuation
- 2001-01-18 UA UAA200612100A patent/UA89180C2/en unknown
- 2001-01-18 UA UA2002086809A patent/UA81388C2/en unknown
- 2001-03-21 SA SA01210754A patent/SA01210754B1/en unknown
-
2007
- 2007-08-17 HR HRP20070360AA patent/HRP20070360B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HRP20070360B1 (en) | 2014-11-21 |
PE20011051A1 (en) | 2001-10-17 |
UA89180C2 (en) | 2010-01-11 |
UA81388C2 (en) | 2008-01-10 |
AR035633A1 (en) | 2004-06-23 |
CO5280075A1 (en) | 2003-05-30 |
HRP20070360A2 (en) | 2008-12-31 |
SA01210754B1 (en) | 2007-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU54602A (en) | Drospirenone for hormone replacement therapy | |
MADANES et al. | Danazol | |
NZ516502A (en) | Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG) | |
CA2205897A1 (en) | Compositions and methods for contraception and for treatment of benign gynecological disorders | |
KR20090080989A (en) | USE OF ESTRADIOL VALERATE OR 17beta-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO | |
WO1996019997A1 (en) | Compounds with progesterone-antagonistic and anti-oestrogen properties intended for combined use in female contraception | |
US20110009373A1 (en) | Composition comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis | |
Thorneycroft | Update on androgenicity | |
TR199900764T2 (en) | A hormonal composition consisting of an estrogen compound and a progestational compound. | |
JO2334B1 (en) | Drospirenone for hormone replacement therapy | |
Shulman | A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone | |
CA2248841C (en) | Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy | |
Whitehead | Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data | |
HRP20020666A8 (en) | Drospirenone for hormone replacement therapy | |
Schindler | Antriandrogen therapy for signs of androgenization: an overview | |
Schindler | COMPOUND CEMICAL STRUCTURE Cimetidine Flutamide | |
TH134365B (en) | Drospirinone for hormone replacement therapy | |
MXPA98007513A (en) | Sequencial combination of estrogen / antagonist of progesterone for therapy of replacement of hormo | |
DE10134768A1 (en) | Pharmaceutical combination preparations containing aromatase inhibitors and substances with an estrogenic effect and their use | |
AU5942700A (en) | Sequential estrogen/progestrone antagonist combination for hormone replacement theapy | |
MXPA01008772A (en) | Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding | |
TH134365A (en) | Drospirinone for hormone replacement therapy |